Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immunic, Inc.NASDAQ: IMUX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $25.63M rose 19.0% year over year, ahead of the +3.9% change in trailing-twelve-month research & development. Sequentially, it rose 34.4% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +19.0% holds above the trailing-twelve-month pace of +3.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 81.98M USD
- Year-over-year change
- +2.4%
- 4-year CAGR
- +7.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.98M | +2.4% |
| FY2024 | 2024-12-31 | 80.05M | -3.8% |
| FY2023 | 2023-12-31 | 83.22M | +16.8% |
| FY2022 | 2022-12-31 | 71.26M | +16.6% |
| FY2021 | 2021-12-31 | 61.12M | — |
Research & Development vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 research & development of $86.08M is the 4th highest of the 9 companies compared; the peer median is $63.68M.
- Its year-over-year change of +3.9% is the 3rd highest of 9, against a peer median of -8.6%.
- Over three fiscal years its annual growth of +4.8% compares with a peer median of +17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $93.8M | -4.5% | +11.6% | — | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| Peer median (excluding IMUX) | $63.68M | -8.6% | +17.8% | 959.3% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.